Clinic
ST. Mary's Health, INC.
ST. Mary's Health, INC. was paid $34.51M by Medicaid between Jan 2018 and Dec 2024, across 168 billing codes. Its largest line is 99283, emergency room visit (moderate) — 21% of everything it billed.
33Billing provider infoST. MARY'S HEALTH, INC.
EVANSVILLE, IN 47750
EVANSVILLE, IN 47750
33aNPI1427082957assigned 07/10/2006
33bProvider typeClinic/Center
28Total paid$34.51M
24GClaims759,971
24DCodes billed168
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinic/Center providers in Indiana
Rank by total paid#2 of 53
Median peer was paid$101K
This provider vs. median342×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 112,079 | $1.75M | |
| 2019 | 95,983 | $2.91M | |
| 2020 | 99,478 | $4.12M | |
| 2021 | 133,622 | $6.40M | |
| 2022 | 131,087 | $7.64M | |
| 2023 | 112,065 | $6.92M | |
| 2024incomplete | 75,657 | $4.78M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 21% | 51,036 | 45,916 | $7.25M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 15% | 53,040 | 43,194 | $5.30M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.9% | 30,030 | 25,858 | $3.07M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 5.4% | 31,679 | 26,654 | $1.86M |
| 96361 | Intravenous infusion, hydration; each additional hour | 5.2% | 17,838 | 13,470 | $1.80M |
| 94761 | 4.1% | 24,676 | 20,278 | $1.43M | |
| 71045 | Radiologic examination, chest; single view | 3.8% | 12,393 | 9,729 | $1.32M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.6% | 29,295 | 23,757 | $1.26M |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 3.2% | 2,049 | 778 | $1.10M |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 3.0% | 15,238 | 13,575 | $1.03M |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2.8% | 23,638 | 21,588 | $983K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.8% | 3,190 | 2,415 | $976K |
156 more codes
| 71046 | Radiologic examination, chest; 2 views | 2.7% | 9,277 | $948K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 2.2% | 1,198 | $776K |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | 1.6% | 1,005 | $551K |
| 80053 | Comprehensive metabolic panel | <1% | 61,086 | $337K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 6,355 | $295K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 69,100 | $282K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 1,768 | $270K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 6,590 | $254K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 19,090 | $249K |
| 80306 | <1% | 23,430 | $215K | |
| 87634 | <1% | 4,140 | $208K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,617 | $151K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 5,612 | $151K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 5,615 | $151K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 104 | $129K |
| 84484 | <1% | 19,676 | $129K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 963 | $119K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 52 | $112K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 2,873 | $106K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 87 | $102K |
| 81025 | <1% | 16,657 | $98K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 34,486 | $96K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 19,561 | $81K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 754 | $81K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 808 | $76K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 6,722 | $68K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 370 | $66K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 184 | $59K |
| 81001 | <1% | 34,244 | $57K | |
| 87088 | <1% | 13,388 | $54K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 4,597 | $50K |
| 83880 | <1% | 2,550 | $47K | |
| 76818 | <1% | 315 | $46K | |
| 83690 | <1% | 15,081 | $44K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 918 | $41K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 473 | $33K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 6,689 | $32K |
| 64415 | <1% | 281 | $28K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 204 | $26K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,366 | $26K |
| G0378 | Hospital observation service, per hour | <1% | 332 | $24K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,217 | $24K |
| 84439 | <1% | 4,329 | $23K | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 1,806 | $21K |
| 83605 | <1% | 3,486 | $18K | |
| 74018 | <1% | 138 | $18K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 104 | $18K |
| 99217 | <1% | 28 | $17K | |
| 83735 | <1% | 3,984 | $13K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 898 | $13K |
| 93325 | <1% | 954 | $13K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 43 | $12K |
| 99218 | <1% | 21 | $12K | |
| 87481 | <1% | 898 | $10K | |
| 80061 | Lipid panel | <1% | 1,043 | $10K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 614 | $10K |
| 93320 | <1% | 890 | $9K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 261 | $8K |
| 80069 | <1% | 2,118 | $8K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 183 | $8K |
| 85610 | <1% | 4,014 | $7K | |
| 93017 | <1% | 100 | $7K | |
| 86140 | <1% | 2,342 | $7K | |
| 82553 | <1% | 2,203 | $7K | |
| 82550 | <1% | 2,482 | $7K | |
| 85730 | <1% | 2,500 | $7K | |
| 82728 | <1% | 600 | $7K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 456 | $7K |
| 85379 | <1% | 1,150 | $7K | |
| 83970 | <1% | 404 | $6K | |
| 80055 | <1% | 211 | $6K | |
| 82570 | <1% | 2,099 | $6K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 18 | $6K |
| 83721 | <1% | 1,013 | $6K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 61 | $5K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 211 | $5K |
| 80050 | General health panel | <1% | 71 | $4K |
| 85652 | <1% | 2,730 | $4K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 99 | $4K |
| 82948 | <1% | 776 | $4K | |
| 99234 | <1% | 24 | $3K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,665 | $3K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 596 | $3K |
| 83655 | <1% | 279 | $3K | |
| 85027 | <1% | 721 | $3K | |
| 87807 | <1% | 431 | $3K | |
| 82043 | <1% | 879 | $3K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 60 | $3K |
| 87081 | <1% | 643 | $3K | |
| 82565 | <1% | 964 | $3K | |
| 96376 | <1% | 66 | $3K | |
| 82607 | <1% | 192 | $3K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 27 | $2K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 14 | $2K |
| 82746 | <1% | 179 | $2K | |
| 97597 | <1% | 102 | $2K | |
| 81003 | <1% | 1,784 | $2K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 12 | $2K |
| 86803 | <1% | 186 | $2K | |
| 87430 | <1% | 562 | $2K | |
| 87070 | <1% | 230 | $2K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 27 | $2K |
| 80076 | <1% | 343 | $2K | |
| 86592 | <1% | 362 | $1K | |
| 82150 | <1% | 411 | $1K | |
| 84156 | <1% | 751 | $1K | |
| 76820 | <1% | 28 | $1K | |
| 80143 | <1% | 81 | $1K | |
| 87808 | <1% | 119 | $1K | |
| 82962 | <1% | 417 | $943.84 | |
| 84702 | <1% | 137 | $881.88 | |
| 86900 | <1% | 45 | $866.70 | |
| 82657 | <1% | 68 | $864.63 | |
| 80179 | <1% | 70 | $857.44 | |
| 87040 | <1% | 133 | $801.77 | |
| 97803 | <1% | 82 | $682.00 | |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 20 | $585.65 |
| 87535 | <1% | 41 | $578.71 | |
| 73130 | <1% | 37 | $464.44 | |
| 83550 | <1% | 71 | $463.22 | |
| 83540 | <1% | 91 | $420.55 | |
| 73030 | <1% | 12 | $345.84 | |
| 82950 | <1% | 85 | $338.57 | |
| 85018 | <1% | 149 | $333.60 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 651 | $332.02 |
| 90791 | Psychiatric diagnostic evaluation | <1% | 82 | $330.48 |
| 87205 | <1% | 115 | $328.92 | |
| 96367 | <1% | 29 | $328.86 | |
| 86901 | <1% | 49 | $318.49 | |
| 86160 | <1% | 17 | $316.03 | |
| 87186 | <1% | 95 | $309.05 | |
| 85014 | <1% | 136 | $302.32 | |
| 86850 | <1% | 67 | $294.24 | |
| 82310 | <1% | 89 | $270.01 | |
| 87340 | <1% | 27 | $224.65 | |
| 87077 | <1% | 80 | $221.87 | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 30 | $183.36 |
| 82330 | <1% | 62 | $182.97 | |
| 86225 | <1% | 16 | $164.60 | |
| 84703 | <1% | 75 | $161.32 | |
| 86800 | <1% | 18 | $141.58 | |
| 76998 | <1% | 28 | $96.74 | |
| 87905 | <1% | 17 | $73.32 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 595 | $63.31 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 41 | $49.77 |
| 84450 | <1% | 12 | $38.28 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 366 | $34.00 |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 18 | $10.80 |
| 76942 | 0% | 198 | $0.00 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 141 | $0.00 |
| 88300 | 0% | 52 | $0.00 | |
| A9270 | Non-covered item or service | 0% | 324 | $0.00 |
| 90870 | 0% | 17 | $0.00 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 23 | $0.00 |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | 0% | 12 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 18 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCHANG, ALEXANDER (CEO)
| Provider | Location | Paid |
|---|---|---|
| ST. Mary's Health, INC. | Evansville, IN | $9K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.